Visit Aggrego Advances hub to learn more about the late breaking developments from the POSEIDON trial 

Top Stories
Association of Geriatric Measures and Global Frailty With Cognitive Decline After Allogeneic Hematopoietic Cell Transplantation in Older Adults

In this study, researchers determined that baseline geriatric measures and frailty and frailty were not associated with significant cognitive change among adult

Journal of Geriatric Oncology
Development and Validation of a Novel TNM Staging N-Classification of Oral Cavity Squamous Cell Carcinoma

Among patients with resected oral cavity squamous cell carcinoma, a new N-classification improved staging performance when compared against TNM-8-N.

Utilizing Biomarkers to Optimize Treatment for Upper Gastrointestinal Cancers

At the Great Debates & Updates in Gastrointestinal Malignancies meeting, Nataliya Uboha, MD, PhD, University of Wisconsin, Carbone Cancer Center, Madison, Wi

Oncology Learning Network


Results of late-breaking developments from the POSEIDON Phase III trial revealed improved overall survival with a limited course of five cycles of tremelimumab added to durvalumab plus platinum chemotherapy.